ENA Respiratory
- Biotech or pharma, therapeutic R&D
ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections through the development of antiviral host defence enhancers, which locally prime and boost the body’s natural first line of defence against invading pathogens. Being virus-agnostic, ENA’s approach offers a solution to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.
The company’s lead product, INNA-051, is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of symptomatic viral respiratory infections and prevent severe complications in at-risk populations, including those with chronic lung conditions.
The company has been awarded a US$13.1M contract from the US DoD to support INNA-051 development. It is an alumni member of BLUE KNIGHT™, a BARDA and Johnson & Johnson initiative designed to accelerate novel solutions for future pandemics.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}